News & Blog
News & Blog
Press Release and Community Statement: Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia
June/July 2025 – Advocacy Newsletter
Press Release: Muscular Dystrophy Association and Friedreich’s Ataxia Research Alliance Announce New Collaborative Grant to Study Cardiac Fibrosis in Friedreich’s Ataxia
Press Release: Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich’s Ataxia Program
Press Release and Community Statement: Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
Webinar Recording: Biogen May 2025 Update
Webinar Recording: Lexeo Therapeutics May 2025 Update
Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
Gehr Family shares their FA journey, how they raise awareness of Friedreich’s ataxia, and the upcoming Cure FA Soirée with local media outlets
Community Statement: Biogen announces BRAVE Phase 3 Pediatric Study of Omaveloxolone